Quick Answer
MANGOCEUTICALS, INC. reported Total Revenue of $615.9 thousand for fiscal year 2024.
MANGOCEUTICALS, INC. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Total Revenue | $615.9K -15.8% |
$731.5K +8083.2% |
$8.9K | — |
| Net Income | -$8.71M +5.5% |
-$9.21M -361.1% |
-$2.00M | — |
| Diluted EPS | -$4.84 +43.6% |
-$8.58 -4415.8% |
-$0.19 | — |
| Total Assets | $15.37M +1362.8% |
$1.05M +4.7% |
$1.00M | — |
| Cash and Equivalents | $58.7K -92.1% |
$739.0K +8.2% |
$682.9K | — |
| Stockholders Equity | $13.95M +1700.1% |
$774.8K +26.2% |
$614.0K +3772.4% |
-$16.7K |
| Operating Income | -$7.97M +13.5% |
-$9.22M -362.9% |
-$1.99M | — |
| Gross Profit | $380.0K -11.9% |
$431.5K +8796.9% |
$4.8K | — |
| Shares Outstanding | 32.02M +2142.3% |
1.43M -89.3% |
13.37M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $84.2K | -36.8% | -49.9% |
| Net Income | September 30, 2025 | -$7.62M | -281.1% | -40.7% |
| Diluted EPS | September 30, 2025 | -$0.69 | +39.5% | -21.1% |
| Total Assets | September 30, 2025 | $16.53M | +11.8% | -20.7% |
| Cash and Equivalents | September 30, 2025 | $481.3K | +551.2% | +376.4% |
| Stockholders Equity | September 30, 2025 | $15.73M | +17.5% | -18.3% |
| Operating Income | September 30, 2025 | -$7.54M | -329.0% | -43.2% |
| Gross Profit | September 30, 2025 | $50.9K | -38.4% | -43.4% |
| Shares Outstanding | September 30, 2025 | 13.88M | -56.6% | +30.4% |
- MANGOCEUTICALS, INC. reported Total Revenue of $615.9 thousand for fiscal year 2024.
- MANGOCEUTICALS, INC. showed a decrease of -15.8% in Total Revenue compared to the prior fiscal year.
- MANGOCEUTICALS, INC. reported Net Income of -$8.71 million for fiscal year 2024.
- MANGOCEUTICALS, INC. showed an increase of +5.5% in Net Income compared to the prior fiscal year.
- MANGOCEUTICALS, INC. reported Diluted EPS of $4.84 per share (loss) for fiscal year 2024.
- MANGOCEUTICALS, INC. showed an increase of +43.6% in Diluted EPS compared to the prior fiscal year.
- MANGOCEUTICALS, INC. reported Total Assets of $15.37 million for fiscal year 2024.
- MANGOCEUTICALS, INC. showed an increase of +1362.8% in Total Assets compared to the prior fiscal year.
- MANGOCEUTICALS, INC. reported Cash and Equivalents of $58.7 thousand for fiscal year 2024.
- MANGOCEUTICALS, INC. showed a decrease of -92.1% in Cash and Equivalents compared to the prior fiscal year.
- MANGOCEUTICALS, INC. reported Stockholders Equity of $13.95 million for fiscal year 2024.
- MANGOCEUTICALS, INC. showed an increase of +1700.1% in Stockholders Equity compared to the prior fiscal year.
- MANGOCEUTICALS, INC. reported Operating Income of -$7.97 million for fiscal year 2024.
- MANGOCEUTICALS, INC. showed an increase of +13.5% in Operating Income compared to the prior fiscal year.
- MANGOCEUTICALS, INC. reported Gross Profit of $380.0 thousand for fiscal year 2024.
- MANGOCEUTICALS, INC. showed a decrease of -11.9% in Gross Profit compared to the prior fiscal year.
- MANGOCEUTICALS, INC. reported Shares Outstanding of 3.25 million shares for fiscal year 2024.
- MANGOCEUTICALS, INC. showed an increase of +52.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: